MYRIAD GENETICS, INC. Payment for Debt Extinguishment or Debt Prepayment Cost
MYRIAD GENETICS, INC. (MYGN) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $600.00 thousand for the 12-month period ending 2017-06-30, per its 10-K filed 2018-08-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2018-08-24
- MYRIAD GENETICS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2017-06-30 was $0.00.
- MYRIAD GENETICS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2017-03-31 was $0.00.
- MYRIAD GENETICS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2017 was $600.00K.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | $0.00 derived: sum of 2 quarters · filed 2018-08-24 | $600.00K 10-K · filed 2018-08-24 | |
| 2017-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $600.00K 10-Q · filed 2018-05-09 | ||
| 2016-12-31 | $600.00K 10-Q · filed 2018-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |